1979
Treatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion.
Canellos G, Sutliffe S, DeVita V, Lister T. Treatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion. Blood 1979, 53: 1014-7. PMID: 435637, DOI: 10.1182/blood.v53.5.1014.bloodjournal5351014.Peer-Reviewed Original ResearchConceptsSplenic artery infusionArterial infusionBlastic phase of chronic granulocytic leukemiaRefractory to previous therapyPhase of chronic granulocytic leukemiaChronic granulocytic leukemiaResponse to treatmentBlastic phasePrevious therapyMassive splenomegalyMyeloproliferative diseaseSystemic toxicityGranulocytic leukemiaSpleen sizeSymptomatic reliefCytosine arabinosidePatientsSplenomegalyInfusionTreatmentHypersplenismPainLeukemiaTherapyArabinosideTreatment of Refractory Splenomegaly in Myeloproliferative Disease by Splenic Artery Infusion
Canellos G, Sutliffe S, DeVita V, Lister T. Treatment of Refractory Splenomegaly in Myeloproliferative Disease by Splenic Artery Infusion. Blood 1979, 53: 1014-1017. DOI: 10.1182/blood.v53.5.1014.1014.Peer-Reviewed Original ResearchSplenic artery infusionArterial infusionBlastic phase of chronic granulocytic leukemiaRefractory to previous therapyPhase of chronic granulocytic leukemiaChronic granulocytic leukemiaResponse to treatmentBlastic phasePrevious therapyMassive splenomegalyMyeloproliferative diseaseSystemic toxicityGranulocytic leukemiaSpleen sizeSymptomatic reliefCytosine arabinosidePatientsSplenomegalyInfusionTreatmentHypersplenismPainLeukemiaTherapyArabinoside
1973
Streptozotocin for Malignant Insulinomas and Carcinoid Tumor: Report of Eight Cases and Review of the Literature
Schein P, Kahn R, Gorden P, Wells S, DeVita V. Streptozotocin for Malignant Insulinomas and Carcinoid Tumor: Report of Eight Cases and Review of the Literature. JAMA Internal Medicine 1973, 132: 555-561. DOI: 10.1001/archinte.1973.03650100069013.Peer-Reviewed Original ResearchMalignant insulinomaBone marrow depressionDrug dose levelsPeak serum concentrationComplete remissionMarrow depressionMetastatic insulinomaObjective responseCarcinoid tumorsMalignant carcinoidSerum concentrationsInfusion rateLow doseStreptozotocinDose levelsInjection sitePatientsInsulinomaLimited responseRemissionCarcinoidsResponseChemotherapyPainTumors
1972
Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.
Bagley C, Canellos G, Young R, Gallelli J, Devita V. Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemotherapy Reports 1972, 56: 387-91. PMID: 19051499.Peer-Reviewed Original ResearchConceptsClinical trialsDose-limiting toxic effectPhase II trialBone marrow toxicityConsecutive daily injectionsTime of onsetDegree of severitySevere nauseaII trialObjective responseDaily injectionsMarrow toxicityPatientsTrialsToxic effectsToxicityNauseaVomitingPainLymphomaMelanomaTumorsLymphosarcomaAdministrationDose
1969
Aspergillus Lobar Pneumonia
Young R, Vogel C, DeVita V. Aspergillus Lobar Pneumonia. JAMA 1969, 208: 1156-1162. PMID: 5818713, DOI: 10.1001/jama.1969.03160070034008.Peer-Reviewed Original ResearchConceptsPleuritic chest painConsistent with pathological findingsLobar pneumoniaChest painPulmonary embolismFungal pneumoniaLobar consolidationVascular invasionHematopoietic malignanciesAspergillus fumigatusClinical symptomsPathological findingsPneumoniaBacterial agentsPatientsAspergillosisHemoptysisChemotherapyPneumonitisCorticosteroidsLeukopeniaMalignancyEmbolizationHemorrhagePain